Global Capecitabine Market growing at a CAGR of 5.5% from 2023 to 2030

Category : Pharmaceuticals And Healthcare | Published Date : Aug 2023

Key Market Overview

Consegic Business Intelligence analyzes that the capecitabine market is predicted to grow at a compound annual growth rate of 5.5% from 2023 to 2030 and is expected to reach USD 1,558.74 million in 2030 which was valued at USD 1,020.00 million in 2022.

The report highlights the increasing adoption of capecitabine in hospitals, which is supplementing global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the capecitabine market.

Global Capecitabine Market By Overview

Global Capecitabine Market

The capecitabine market is bifurcated into form, indication, and end user. Based on form, the market is segmented into tablets and powder. In 2022, the tablets segment dominate in the overall capecitabine market. The indication segment is categorized into breast cancer, colorectal cancer, gastric cancer, and others. In 2022, the breast cancer segment accounted for the highest market share in the capecitabine market. In the context of end user, the market is segmented into hospitals, specialty clinics, homecare, and others. In 2022, the hospitals segment dominate in the overall capecitabine market.

Get Free Sample

Market Dynamics



  • The rising prevalence of cancer cases is driving the adoption of capecitabine, which is fostering market growth.
  • Increasing adoption of capecitabine is propelling the growth of the capecitabine market at the global level.



  • Various side effects associated with the utilization of capecitabine is restraining the market growth.

Market Segmentation:

Report Attributes Report Details
By Form Tablets and Powder
By Indication Breast Cancer, Colorectal Cancer, Gastric Cancer, and Others
By End Use Hospitals, Specialty Clinics, Homecare, and Others
By Region North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Competitive Landscape :

As per the study, the market is dominated by certain major companies such as Teva Pharmaceuticals, Inc, F. Hoffmann-La Roche AG, Mylan N.V., and Hikma Pharmaceuticals PLC which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the capecitabine market is expected to witness substantial growth in the coming years due to the increasing development of new hospital facilities in key regions such as North America, Asia Pacific, and others.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.

  • Teva Pharmaceuticals, Inc
  • F. Hoffmann-La Roche AG
  • Mylan N.V.
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Sun Pharmaceutical Industries Limited
  • Genentech, Inc.
  • Accord Healthcare Ltd.